A retrospective study of IVIG (octagam® 5%) in Critically Ill COVID-19 Patients
Latest Information Update: 21 Apr 2021
At a glance
- Drugs Immune globulin (Primary) ; Anakinra; Azithromycin; Favipiravir; Hydroxychloroquine; Oseltamivir; Tocilizumab
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- 01 Apr 2021 Results published in the Current Medical Research and Opinion
- 20 Jul 2020 New trial record
- 15 Jul 2020 According to an Octapharma media release, this study was conducted at the Istanbul University Hospital, Turkey, under the lead of Prof. Dr. Figen Esen.